|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,951.75 GBX | +1.57% |
|
+2.58% | +6.93% |
| 07:02am | Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal | RE |
| 06-10 | Intron Health Upgrades GSK to Hold Rating, Lifts PT | MT |
Evolution of the Average Target: GSK plc
Evolution of the Target Price: GSK plc
Changes in Analyst Recommendations: GSK plc
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +8.07% | |||||
| +6.99% | |||||
| +6.03% | |||||
| +12.71% | |||||
| +11.38% | |||||
| +22.5% | |||||
| +4.03% | |||||
| +4.37% | |||||
| +10.13% | |||||
| +29.92% | |||||
| Average | +11.61% | |||||
| Weighted average by Cap. | +9.96% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Intron Health | |
| JPMORGAN | Zain Ebrahim |
| UBS | Matthew Weston |
| BARCLAYS | James Gordon |
| JEFFERIES | Michael Leuchten |
| Morningstar | |
| BERNSTEIN RESEARCH | Justin Smith |
| alphavalue | Abhishek Raval |
| GOLDMAN SACHS | Rajan Sharma |
| DZ BANK | Elmar Kraus |
| AlphaValue/Baader Europe | |
| BERENBERG | Kerry Holford |
| Citigroup | |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| Berenberg Bank | |
| Sadif Investment Analytics | |
| BNP Paribas Exane | |
| Jefferies & Co. | |
| Guggenheim | |
| HSBC | |
| LBBW | |
| Bernstein | |
| Deutsche Bank Securities | |
| Morgan Stanley | |
| CREDIT SUISSE | Dominic Lunn |
| Bank of America Securities/Merrill Lynch | |
| Stifel Nicolaus | |
| ODDO BHF | |
| Societe Generale | |
| Liberum Capital | |
| J.P. Morgan Chase | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| KEPLER CHEUVREUX | David Evans |
| BAADER BANK | |
| SVB Leerink | |
| BANK OF AMERICA (BOFA) | Graham Parry |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- Consensus GSK plc
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition